Skip to main content

In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4.

Publication ,  Journal Article
Romiti, GF; Talerico, G
Published in: Ann Intern Med
November 2024

Lopes RD, Granger CB, Wojdyla DM, et al. Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA. J Am Coll Cardiol. 2024;84:354-364. 39019530.

Duke Scholars

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

November 2024

Volume

177

Issue

11

Start / End Page

JC125

Location

United States

Related Subject Headings

  • Stroke
  • Risk Assessment
  • Pyridones
  • Pyrazoles
  • Platelet Aggregation Inhibitors
  • Male
  • Humans
  • General & Internal Medicine
  • Female
  • Factor Xa Inhibitors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Romiti, G. F., & Talerico, G. (2024). In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4. Ann Intern Med, 177(11), JC125. https://doi.org/10.7326/ANNALS-24-02625-JC
Romiti, Giulio Francesco, and Giovanni Talerico. “In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4.Ann Intern Med 177, no. 11 (November 2024): JC125. https://doi.org/10.7326/ANNALS-24-02625-JC.
Romiti, Giulio Francesco, and Giovanni Talerico. “In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4.Ann Intern Med, vol. 177, no. 11, Nov. 2024, p. JC125. Pubmed, doi:10.7326/ANNALS-24-02625-JC.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

November 2024

Volume

177

Issue

11

Start / End Page

JC125

Location

United States

Related Subject Headings

  • Stroke
  • Risk Assessment
  • Pyridones
  • Pyrazoles
  • Platelet Aggregation Inhibitors
  • Male
  • Humans
  • General & Internal Medicine
  • Female
  • Factor Xa Inhibitors